Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI-verified early response to certolizumab pegol in active rheumatoid arthritis
2009-013758-33Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Certolizumab pegol with Placebo control (2 arms). Primary endpoint: First time point with statistically significant reduction in OMERACT RAMRIS synovitis activity score versus baseline. Started Mar 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-013758-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013758-33.